BEST TRADING ALERTS - MAKES 300% WEEKLY RETURN HIGHLY RECOMMENDED
http://www.stocksmastermind.com

Dear Friends:

EcoBlu Products Inc. (OTC: ECOB) has signed an exclusive licensing
agreement with fire protection supplier Megola

Check it Out    http://www.sddt.com/news/article.cfm?SourceCode=20091119czb

An Eco-Friendly WORLD is a DREAM of all and ECO Blu Products ECOB is
one such stepping stone towards it.  www.EcoBluProducts.com

ECOB  Products; a fully integrated chemical coating plant located in
Southern California and Northeast Texas, poised to impact housing
industry on many levels.

ECOB aims at preventing rot, mildew, fungus, termite infestation,
along with effective fire retardant. Coated wood lasts Lifelong;
increases sustainability of forests.

Estimated Market demand for treated lumber is $11 Billion by 2010.
Demand for lumber and engineering wood products is expected to be $18
Billion.

The management team made up to Founder Steve Conboy and EVP Mark
Vuzzo, having more than 30 years of experience each; and the Advisory
team consisting of Ken McClelland- president of McClelland
Organization. The ECoBlu seems to be in have a great leaders.

ECO Blu is superbly positioned to take advantage in this rapidly
increasing eco friendly and Green market.
ECOB  have an estimated growth of about $6 billion within 3 years.
This would represent a gain of over 200% from current level.

The wood chemical market enjoyed $2 Billion in revenues in 2007, ones
the global financial market recovers the revenues are expected to
exceed the numbers.

Partnership with Lowe’s had enabled EcoBlu to implement new strategies
and boost contractor sales.

EcoBlu have established Nationwide Sales and Marketing of coatings
chemistry in South America, Caribbean, Africa and Asia.

A Three year plan of ECOB calls for direct selling of chemicals
coatings to mills, EWP manufacturers and independent coaters in the US
and elsewhere, than just selling to retailers and other small
builders.

Check out Complete Presentation only at www.stockexploder.com

 Please do your own due diligence on ECOB

Been a member for 6 months and love it.
Daily live webcasts are awesome, learning and making money at the same
time.
Best I have ever seen!

TITLE:    Big News Coming Monday for (NASDAQ:CYTR)

BODY:
Market Mafia - http://groups.google.ca/group/market-mafia
We're hearing rumours swirling from several sources that
BioMedReports' next company profile will be on (NASDAQ:CYTR), with
some big headlines about to be announced, and perhaps even with their
phase III Lukemia treatment. This stock promises to deliver and be a
big play for Monday.
Shares of this biopharmaceutical research and development company
gapped up on Friday's close on higher than usual morning volume and
are chasing a rumor in the newsroom. We're hearing some interesting
developments are taking place at CytRx Corporation (NASDAQ:CYTR) and
that the company may have multiple news items coming that may impact
share price in the coming days.
Two days ago, the company announced plans to initiate an open-label,
multinational Phase 2 clinical trial with its doxorubicin prodrug
INNO-206 as a second-line treatment in patients with advanced gastric
(stomach) cancer.
Should the company receive news about their long-awaited phase III
trials being cleared to begin, the shares are bound to skyrocket, as
seen by many other previous small biotech companies who have entered
important clinical trials, and make their way into new drug
application status.
Keep a close eye on it tomorrow and get in as early as you as it will
surely be a dogfight for those shares, and remember to join Market
Mafia for regular picks chosen by expert analysts and researchers at
http://groups.google.ca/group/market-mafia
Thank you for your time and happy trading!

Market Mafia - http://groups.google.ca/group/market-mafia
We're hearing rumours swirling from several sources that
BioMedReports' next company profile will be on (NASDAQ:CYTR), with
some big headlines about to be announced, and perhaps even with their
phase III Lukemia treatment. This stock promises to deliver and be a
big play for Monday.
Shares of this biopharmaceutical research and development company
gapped up on Friday's close on higher than usual morning volume and
are chasing a rumor in the newsroom. We're hearing some interesting
developments are taking place at CytRx Corporation (NASDAQ:CYTR) and
that the company may have multiple news items coming that may impact
share price in the coming days.
Two days ago, the company announced plans to initiate an open-label,
multinational Phase 2 clinical trial with its doxorubicin prodrug
INNO-206 as a second-line treatment in patients with advanced gastric
(stomach) cancer.
Should the company receive news about their long-awaited phase III
trials being cleared to begin, the shares are bound to skyrocket, as
seen by many other previous small biotech companies who have entered
important clinical trials, and make their way into new drug
application status.
Keep a close eye on it tomorrow and get in as early as you as it will
surely be a dogfight for those shares, and remember to join Market
Mafia for regular picks chosen by expert analysts and researchers at
http://groups.google.ca/group/market-mafia
Thank you for your time and happy trading!

TIME TO SELL ALL STOCKS, DOW WILL FALL TO 7000 - 8000 LEVEL, STOCKS
WILL KEEP FALLING UNTIL MID 2010

Dear Friends:

Our Exploding New Pick is Vivakor, Inc. VIVK http://www.vivakor.com/

VIVK is a trans-disciplinary biomedical/biotechnology company involved
in Discovering, Developing and Commercializing Solutions that
positively impact life. www.vivakor.com

VIVK plans to adapt a $300 Million potential technology upgrade to
produce and enhance MRI images which might improve MRI resolution
along with providing additional data such a blood flow velocity in
images tissues.

Market potential of about $15 Million just within 12 month
commercialization of the electro-optical devices released by VIVK.

VIVK have a fully integrated specialist team working on clinical trial
on Digital Photo screener, Opti-Ear and Anemia Monitor, having a
completion time of late 2009, positive results may drastically reduce
overall time and cost from previously used technology.

Experienced BOD Matthew Nicosia, Dr.Tannin Fuju and John Grayga have
strategically grown the revenue of VIVK from $20 Million to $120
Million. They approved a dividend to every share holders. Each share
holder will receive one HealthAmerica share for every share of Vivakor
Inc.

VIVK is currently in collaboration with University of IOWA, developing
a digital photo refractor that is intended to modernize child vision
screening. Approval has been granted from Western Institutional Review
Borad(20080731) to conduct human validation study.

VIVK has developed a series of nutraceutical formulations, including
VivaBlend, and plan to develop additional nutraceuticals, botanicals
and supplements. VIVK recently received 25000 units purchase order for
one of their products.

Critical advancement in the biological sample preservation are also
been evolved in VIVK. They have developed specialized Cryovials that
accommodate an improved method of cryopreservation of cells, blood and
other bio-materials.

VIVK have recently launched its sales products to Exploding Indian
Biotech market. Biopharma remains India’s biggest sector, accounting
for nearly 70% of the total revenues, expected to be worth US $5.7
Billion by 2012-2013. The future of the bio-supplier industry in India
looks very bright and so does of VIVK.

Check out Complete Presentation only at www.stockexploder.com

Please do your own due diligence on VIVK
All The Best

Exploder

www.stockexploder.com

 *Never invest in a stock mentioned by stockexploder.com unless you
can afford to lose your entire investment. For full disclaimer
http://www.stockexploder.com/disclaimer.html
Reply

Reply to all

Forward

sto

PREDICTION, TIME TO BUY ALL STOCKS, STOCKS KEEP RISING UNTIL MID

On Nov 19, 10:42 am, randy <thubu...@gmail.com> wrote:

just found this article... http://www.pearl-invest.net/hot-deals-of-the-financial-crisis/

PREDICTION, TIME TO SELL ALL STOCKS, STOCKS KEEP FALLING UNTIL MID
2010. BIDU WILL FALL TO $200 - $250 LEVEL NEXT COUPLE MONTHS

Dear Friends :

SINOBIOPHRMA INC "soared" 93% with two trading Days after my alert !
Congratulations!!!

Today SINOBIOPHRMA INC traded as high of  0.39 on over 5,000,000
shares traded

I gave this to you at 0.20 for Monday's trade....

Ok, so what’s next you ask? I have something even bigger...

Why it's in your best interest to buy  and Full Presentation on Entest
BioMedical Inc

Bio-tech companies are a great investment right now, according to many
financial experts. Support from the Obama administration will ensure
this trend continues.

Between the current administration rallying behind Bio-tech and
Stimulus plan. This is a great combo to ensure if you pick the right
Bio-tech stock you can make massive gains quickly.

"WALL STREET IS ALWAYS LOOKING” For the Next Big Thing.......

Whether it's a cure for cancer or a fountain of youth , the script
can be all-too-familiar Financially, 2009 has been a hard year.

Almost every industry sector has suffered....

But financial experts wouldn't be experts if they couldn't find a
sector that will do better than the others, and that will offer
substantial returns

to investors.

Biotech is what they recommend

Forbes interviewed two top-notch analysts in this area, Eric Schmidt
and Ross Muken. They both agree that there is money to be made by
investing in biotech.

Bottom line is this... You have a choice,

You can take action and buy Entest BioMedical Inc now!
or wait to buy it at potentially $3.50 per share

This is set to soar!!

Exploder

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Market Mafia - http://groups.google.ca/group/market-mafia

Power3 Medical is a breakthrough proteomics company specializing in
the identification of disease footprints in the areas of
chemotherapeutic drug resistance and the early detection of breast
cancer and neurological diseases opposed to late stage detection.

They have recently filed for 3 utility patents due to their advances
in early stage breast canc
 Proteomics is the study and analysis of proteins, the fundamental
building blocks of the human body. By studying proteins, scientists
can understand more fully the functioning of a healthy body and
identify the proteins associated with specific diseases. Proteins are
not only the building blocks for life; in them, evidence can be found
for serious diseases such as cancer, neurodegenerative disease
     * Breast Cancer
    * Alzheimer’s Disease
    * ALS (Lou Gehrig’s Disease)
    * Parkinson’s Disease
    * Leukemia
    * Gastrointestinal Disease
    * Metabolic Syndrome
    * Chemotherapeutic Drug Resistance

 These discovered and patent-pending biomarkers solve critical
challenges facing pharmaceutical and diagnostic companies and are
currently being used to design tests to diagnose diseases and discover
targets for new drugs to treat the diseases.

Each validated biomarker, pattern, new diagnostic test, or drug
target, may have a potential market value from $10 – $100 million plus

RECENT NEWS:

 PWRM Announced that its Chief Scientific Officer is Chair and Keynote
Speaker of Session at the BTI Life Sciences 2nd Annual Congress and
Expo of Molecular Diagnostics in Beijing, China in November 2009

Further international recognition of validity as the company’s
President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote
address and chair a session on “Biomarkers and Diagnostics in
Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd
International Congress and Expo of Molecular Diagnostics in Beijing,
China, November 19-21, 2009. The Theme of the meeting is “New
Leadership

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Dear Friends:

SNBP is our New Pick www.sinobiopharma.com

SINO BIOPHARMA SNBP a Fully integrated specality biopharmaceutical
company with 30,000 sq.meter Certified Production Facilities in China.

Estimated Chinese Health Care Market Demand of $600 Billion by 2015.We
all are aware China’s Current population is 1.4 Billion.

SNBP traded as high as $2.0 in the PAST, we can shoot for a gain of
8400%

Leadership of CEO Dr. Lequn Lee Huang a former manager of the Bayer
Co., one of the world's largest pharmaceutical companies and CFO Mr.
Dong Ying formerly of JP Morgan Chase.

SNBP Anesthetics Projected sale of 1.5 million units and 500,000
tablets for cardiovascular diseases in 2009.

Key Drives:
Outstanding financial results; more than 2000% growth in 3 years.
4 key marketed products; multiple products in pipeline.
R&D Partnership with Cornell University and 3 Top Universities in
China.
Established Nation wide Sales and Marketing Network in China.
Aging Population & Increasing Life Style diseases.
Improving Health Insurance Programs and Coverage.

PLAN FOR FUTURE: Sinobiopharma has a clearly defined strategy to drive
short, middle and long term growth.  All drug development will
leverage the Company's patented technology for fast, low-cost drug
synthesis and new technology for formulation.

Check out Complete Presentation only at www.stockexploder.com
Please do your own due diligence on SNBP
All The Best

Exploder

www.stockexploder.com
 *Never invest in a stock mentioned by stockexploder.com unless you
can afford to lose your entire investment. For full disclaimer
http://www.stockexploder.com/disclaimer.html